# US 9,517,256 B2 · Vaccine and method for treatment of neurodegenerative diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,517,256 B2 - Document ID: US9517256B2 - Status: Granted - Kind: B2 - Application number: 14/162,482 - Filed: 2014-01-23 - Published: 2014-05-15 - Granted: 2016-12-13 - Earliest claimed: 2003-11-12 - Assignees: Yeda Research and Development Co. Ltd. - Applicants: Yeda Research and Development Co., Ltd. - Inventors: Michal Eisenbach-Schwartz; Ester Yoles; Oleg Butovsky; Jonathan Kipnis - Web page: https://patentgrep.com/patent/US9517256B2 ## CPC - A61K 39/0007: {Nervous system antigens; Prions} - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance} - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/22: Immunosuppressive or immunotolerising - A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance} - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia - A61P 25/16: Anti-Parkinson drugs - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii). ## Claims ### Claim 1 A method for treating a neurodegenerative disorder or disease selected from the group consisting of Huntington's disease and Alzheimer's disease, said method comprising administering Copolymer 1 without an adjuvant to an individual in need thereof, wherein said administering is once every 1, 4 or 6 weeks. ### Claim 2 (depends on 1) The method in accordance with claim 1, wherein said neurodegenerative disorder or disease is Alzheimer's disease. ### Claim 3 (depends on 1) The method in accordance with claim 1, wherein said neurodegenerative disorder or disease is Huntington's disease. ### Claim 4 (depends on 1) The method in accordance with claim 1, wherein said administering is once a week. ### Claim 5 (depends on 2) The method in accordance with claim 2, wherein said administering is once a week. ### Claim 6 (depends on 3) The method in accordance with claim 3, wherein said administering is once a week. ### Claim 7 (depends on 1) The method in accordance with claim 1, wherein said administering is once every four weeks. ### Claim 8 (depends on 2) The method in accordance with claim 2, wherein said administering is once every four weeks. ### Claim 9 (depends on 3) The method in accordance with claim 3, wherein said administering is once every four weeks. ### Claim 10 A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from Alzheimer's disease, which comprises administering an effective amount of Copolymer 1 without an adjuvant to an individual in need thereof, wherein said administering is once every 1, 4 or 6 weeks. ### Claim 11 (depends on 10) The method in accordance with claim 10, wherein said administering is once a week. ### Claim 12 (depends on 10) The method in accordance with claim 10, wherein said administering is once every four weeks. ### Claim 13 A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from Huntington's disease, which comprises administering an effective amount of Copolymer 1 without an adjuvant to said patient in need thereof, wherein said administering is once every 1, 4 or 6 weeks. ### Claim 14 (depends on 13) The method in accordance with claim 13, wherein said administering is once a week. ### Claim 15 (depends on 13) The method in accordance with claim 13, wherein said administering is once every four weeks. ### Claim 16 A method for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with Huntington's disease or Alzheimer's disease, said method comprising administering Copolymer 1 without an adjuvant to an individual in need, wherein said administering is once every 1, 4 or 6 weeks. ### Claim 17 (depends on 16) The method in accordance with claim 16, wherein said neurodegeneration and cognitive decline and dysfunction are associated with Alzheimer's disease. ### Claim 18 (depends on 16) The method in accordance with claim 16, wherein said neurodegeneration and cognitive decline and dysfunction are associated with Huntington's disease. ### Claim 19 (depends on 16) The method in accordance with claim 16, wherein said administering is once a week. ### Claim 20 (depends on 17) The method in accordance with claim 17, wherein said administering is once a week. ### Claim 21 (depends on 18) The method in accordance with claim 18, wherein said administering is once a week. ### Claim 22 (depends on 16) The method in accordance with claim 16, wherein said administering is once every four weeks. ### Claim 23 (depends on 17) The method in accordance with claim 17, wherein said administering is once every four weeks. ### Claim 24 (depends on 18) The method in accordance with claim 18, wherein said administering is once every four weeks.